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FailureAbstract Background: CD4,CD8 T cells, T-helper 1 (Th1) and T-helper 2 (Th2) have an impor-
tant role in host defence in pulmonary tuberculosis.
Aim of the work: Evaluate the role of some T-lymphocyte subsets in treatment failure of tuber-
culous patients.
Subjects and methods: This study was carried out on 52 persons divided into 4 groups: group I
control, group II active TB patients, group III Responders to treatment and group IV (non-respon-
ders) .Bronchoalveolar lavage (BAL) and peripheral blood samples from patients and controls were
examined for the frequency of CD4, CD8, Th1 and Th2 cells using ﬂow cytometry.
Results: Bronchoalveolar lavage CD4% was signiﬁcantly increased in group III as compared to
other groups, CD8% was signiﬁcantly increased in group IV as compared to other groups, Th1%
was signiﬁcantly high in group III as compared to other groups. Blood CD4% was increased in
group III as compared to other groups, CD8% was signiﬁcantly increased in groups II and IV
as compared to other groups, Th1%was signiﬁcantly decreased in groups II and IV as compared
to other groups. Th2% was signiﬁcantly increased in group IV as compared to other groups.
Conclusion: CD4, CD8, Th1 and Th2 cells play a major role in immunology against TB infection
and can be used as a marker for response to anti-tuberculous treatment.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
One-third of the world’s population was infected with
Mycobacterium tuberculosis and it remains a major threat topublic health [1] with an estimated 7.5 million cases each year
(more than 95 percent in developing countries) [2].Granuloma
formation is an essential component of host immunity for con-
trolling infection and dependent on activation of mycobac-
teria-reactive T lymphocytes [3], particularly CD4 and CD8
T cells [4,5]. CD4 cells help in antibody production and thus,
they involved in class-II MHC-restricted responses but CD8
cells are cytotoxic cells helping in cell mediated responsesrculosis.
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their surface (class I restricted response) [6]. Granuloma for-
mation, however, is a complex process that requires not only
the activation of the lymphocytes, but also their recruitment
with monocytes to the site of the infection, migration into
the tissues, and juxtaposition around mycobacteria-infected
macrophages [7] .This colocation facilitates the activation of
bactericidal mechanisms in infected macrophages by T cell-
derived cytokines [3]. One theory of immune regulation
involves homeostasis between T-helper 1 (Th1) and T-helper
2 (Th2) activity. Th1 cells drive the type-1 pathway (cellular
immunity) to ﬁght viruses and other intracellular pathogens,
eliminate cancerous cells and stimulate delayed-type hyper-
sensitivity reactions. Th2 cells drive the type-2 pathway
(humoral immunity) and up-regulate antibody production to
ﬁght extracellular organisms. Overactivation of either pattern
can cause disease [8].
Tuberculosis needs new improved vaccine and
immunodiagnostics.CD4 and CD8 cells play an important role
in host defence to TB. Deﬁnition of the antigens recognized by
these T cells is critical for improved understanding of the
immunobiology of TB and for development of vaccines and
diagnostics. Immunodominant antigens and epitopes have
been deﬁned using approaches targeting particular TB proteins
or classes of proteins and by genome-wide discovery
approaches. Antigens and epitopes recognized by CD4and
CD8T cells show extensive breadth and diversity in TB [9].Aim of the work
Evaluate the role of some T-lymphocyte subsets in treatment
failure of tuberculous patients.
Subjects and methods
This study was carried out on 52 tuberculous persons in the
Chest Department, Tanta University Hospitals from
February 2012 to November 2014 and were divided into 4
groups: group I, included 10 non-smoker control persons (5
males, 5 females) and their mean age was 27.2 ± 1.3 years,
group II included 17 non-smoker newly diagnosed active TB
patients, before starting of anti-tuberculous treatment, (9
males, 8 females)and their mean age was 31.2 ± 2.3 years),
group III included 15 non-smoker TB patients completed ini-
tial phase of anti-tuberculous treatment with sputum conver-
sion to negative (9 males, 6 females) and their mean age was
30.2 ± 2.9 years (Responders), and group IV included 10
non-smoker TB patients completed initial phase of anti-tuber-
culous treatment and their sputum was still positive (6 males, 4
females) with the mean age 36.6 ± 4.7 years (non-responders).
All tuberculous patients were collected from many Chest
Hospitals and outpatient clinics. Informed consents were taken
from all participants and the protocol of this work was dis-
cussed with them (Tables 1–8).
Inclusion criteria
TB patients should fulﬁll the following:
1. Clinical manifestation of TB.2. Radiological manifestation of TB.
3. Positive Z.N examination of sputum for acid fast
bacilli.
Exclusion criteria
1. HIV positive patients.
2. Auto-immune diseases.
3. Patients with Lymphoma, Leukaemia or blood
diseases.
4. Patients under cortico-steroids or immune-suppressant
agents.
5. D.M
6. Any contraindication to ﬁberoptic bronchoscopy.
All subjects were subjected to the following:
a. Full history and clinical examination.
b. Plain X-ray chest P.A view.
c. Routine investigations including ESR, complete blood
picture and fasting and post-prandial blood sugar level.
d. Z.N stain examination of sputum 3 successive times.
e. HIV antibody assay by Elisa.
f. Bronchoscopy and broncho-alveolar lavage
(BAL)Bronchoscopy was performed according to stan-
dard guidelines. Thirty minutes prior to the procedure
patients received i.m atropine sulphate ampoule, 1 mg/
ml (C.I.D company) and i.v 5 mg midazolam, 5 mg/ml
(Sunny Pharmaceutical). Local anaesthesia of the
oropharynx was achieved by Lidocaine spray 10%
(Cairo Company) until gag reﬂexes subsided.
Bronchoscopy was performed using Olympus BF type
P10, Tokyo, Japan bronchoscope through which,
Bupivacaine (Al-Debeiky Pharmaceutical) 5 mg/ml was
instilled to keep the tracheo-bronchial tree anaes-
thetized, then, 120 ml of normal saline in aliquots of
20 ml was instilled into a subsegment of the right middle
lobe. BAL ﬂuid was then immediately aspirated by gen-
tle hand suction into plastic tubes and kept at 4 C [10].
g. Examination of blood and BAL for CD4,Th1,Th2 and
CD8 cells percent
- Processing of BAL cells
BAL samples were ﬁltered through a two-layer sterile
gauze into sterile plastic vials (Falcon, Oxnard, CA), cen-
trifuged at 4 C and 500g for 10 min. The supernatant
was removed and cells were washed twice in (phosphate
buffered saline) PBS. The total cell number was counted
using a Neubauer haemocytometer (Brand, Wertheim,
Germany). Differential cell counts were performed after
Giemsa staining (Merck, Darmstadt, Germany) of cell
smears with 1000 cells per slide counted [10].
- Isolation of peripheral blood mononuclear cells
(PBMC)
Venous blood was drawn into sterile plastic containers
containing 0Æ2 ml EDTA (Sarstedt, Nu¨mbrecht,
Germany) prior to the bronchoscopy and was separated
on a gradient of Ficoll with a density of 1Æ077 g/l for
20 min at 1330 g. The band of peripheral blood
mononuclear cells (PBMC) at the interface was col-
lected and washed twice [10].
Table 1 Total leucocyte count, percent of lymphocytes and neutrophils in bronchoalveolar lavage ﬂuid in the 4 groups.
GI GII GIII GIV F test P value
Total leucocyte count Range 430–610 950–1580 420–800 900–1350 70.334 0.001 G1-G2 0.001
G1-G3 0.045
G1-G4 0.001
Mean ± SD 515 ± 50.17 1185 ± 196.24 632 ± 119.83 1127 ± 133.57 G2-G3 0.001
G2-G4 0.330
G3-G4 0.001
Percent of lymphocytes Range 12.8–15.6 19.3–29 13.5–21.2 24.1–35.9 76.830 0.001 G1-G2 0.001
G1-G3 0.005
G1-G4 0.001
Mean ± SD 13.99 ± 1 22.99 ± 2.99 17.15 ± 2.03 30.05 ± 3.76 G2-G3 0.001
G2-G4 0.001
G3-G4 0.001
Percent of neutrophils Range 1.6–3.7 2.4–6.4 2.1–3.9 3.5–6.1 14.392 0.001 G1-G2 0.051
G1-G3 0.385
G1-G4 0.001
Mean ± SD 2.83 ± 0.702 3.52 ± 1.11 3.12 ± 0.571 4.98 ± 0.748 G2-G3 0.206
G2-G4 0.001
G3-G4 0.001
Table 2 Percent of CD4, CD8, Th1 and Th2 cells in bronchoalveolar lavage ﬂuid in the 4 groups.
GI GII GIII GIV F test P value
Percent of CD4 Range 47.8–56.2 32.1–38.9 60.9–78.4 23.7–31.9 63.208 0.001 G1-G2 0.001
G1-G3 0.001
G1-G4 0.001
Mean ± SD 52.62 ± 2.98 35.04 ± 1.81 70.56 ± 5.43 27.18 ± 2.28 G2-G3 0.001
G2-G4 0.001
G3-G4 0.001
Percent of CD8 Range 21.9–26.9 27.5–36.8 15.8–27.01 36.2–44.1 50.033 0.001 G1-G2 0.001
G1-G3 0.013
G1-G4 0.001
Mean ± SD 24.09 ± 1.46 31.99 ± 2.77 21.15 ± 3.61 40.21 ± 2.22 G2-G3 0.001
G2-G4 0.001
G3-G4 0.001
Percent of Th1 Range 35.2–42.1 51.1–59.1 45.0 – 75.0 27.0–55.0 37.443 0.001 G1-G2 0.001
G1-G3 0.001
G1-G4 0.716
Mean ± SD 38.25 ± 1.96 55.15 ± 2.2 62.0 ± 9.63 37.1 ± 9.33 G2-G3 0.014
G2-G4 0.001
G3-G4 0.001
Percent of Th2 Range 0.15–0.39 0.19 – 0.42 0.21 – 0.45 0.19 – 0.48 0.392 0.760 G1-G2 0.470
G1-G3 0.633
G1-G4 0.303
Mean ± SD 0.276 ± 0.09 0.254 ± 0.064 0.262 ± 0.0617 0.242 ± 0.084 G2-G3 0.772
G2-G4 0.705
G3-G4 0.511
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peripheral blood and BAL cells.
PBMC and BAL cells were incubated in the presence of
ﬂuorescein-conjugated MoAb against the surface mark-
ers CD4 & CD8 for 20 min at room temperature in the
dark. Non-speciﬁc ﬂuorescence was detected by
incubating mouse IgG of the same isotype, but with
irrelevant antigen speciﬁcity. After two washes with
PBS the cells were analysed by ﬂow cytometry
(FACSCalibur; Becton Dickinson, Heidelberg,
Germany) [10].- Analysis of Th1 and Th2 in T lymphocytes in PBMC
from peripheral blood and BAL cells.
PBMC and BAL cells were stimulated with 108 m
PMA and 106 m Ca-Ionophore A23187 for 4 h and
cytokine release was blocked by adding brefeldin A
(10 lg/ml). Subsequently cells were washed twice with
PBS/1% fetal calf serum (FCS)/0.1% NaN3 and ﬁxed
in 4% paraformaldehyde in PBS pH 7Æ4 for 15 min on
ice. Cells were then incubated for 30 min at room tem-
perature with (phycoerythrin) PE-conjugated MoAbs
speciﬁc for CD4. Following two washes in PBS/1%
Table 3 Total leucocyte count and percent of lymphocytes in blood in the 4 groups.
GI GII GIII GIV F test P value
Total leucocytic count Range 5500–8100 6500–9500 5800–8200 5900–9100 4.162 0.011 G1-G2 0.014
G1-G3 0.866
G1-G4 0.027
Mean ± SD 6990 ± 884.9 7914.3 ± 918.9 7050 ± 704.3 7890 ± 1054.6 G2-G3 0.010
G2-G4 0.947
G3-G4 0.022
Percent of lymphocytes Range 26.6–35.8 19.5–29.1 23.5–38.3 19.8–28.7 16.592 0.001 G1-G2 0.001
G1-G3 0.667
G1-G4 0.001
Mean ± SD 31.09 ± 3.18 24.19 ± 2.59 30.49 ± 4.37 23.57 ± 2.78 G2-G3 0.001
G2-G4 0.661
G3-G4 0.001
Table 4 Percent of CD4, CD8, Th1 and Th2 in blood in the 4 groups.
GI GII GIII GIV F test P value
Percent of CD4 Range 31.1–41.4 21.7–34.2 32.8–44.9 12.9–22. 101.973 0.001 G1-G2 0.001
G1-G3 0.159
G1-G4 0.001
Mean ± SD 36.54 ± 3.58 27.96 ± 3.51 38.34 ± 2.7 18.03 ± 2.66 G2-G3 0.001
G2-G4 0.001
G3-G4 0.001
Percent of CD8 Range 26–34.5 29.4–39.2 17.4–26.9 30–42.8 68.359 0.001 G1-G2 0.002
G1-G3 0.001
G1-G4 0.001
Mean ± SD 30.2 ± 2.68 34.07 ± 2.92 21.86 ± 2.05 36.29 ± 3.94 G2-G3 0.001
G2-G4 0.068
G3-G4 0.001
Percent of Th1 Range 0.5–2.01 0.2–0.45 0.75–1.7 0.13–0.3 60.905 0.001 G1-G2 0.001
G1-G3 0.560
G1-G4 0.001
Mean ± SD 1.148 ± 0.448 0.308 ± 0.065 1.205 ± 0.229 0.203 ± 0.051 G2-G3 0.001
G2-G4 0.299
G3-G4 0.001
Percent of Th2 Range 8.2–14.8 43.4–57.8 8.6–31 50.9–70.2 41.634 0.001 G1-G2 0.001
G1-G3 0.108
G1-G4 0.001
Mean ± SD 11.13 ± 1.81 50.73 ± 3.91 14.16 ± 4.83 61.11 ± 5.31 G2-G3 0.001
G2-G4 0.001
G3-G4 0.001
Table 5 CD4/CD8 ratio in BAL in the 4 groups.
CD4/CD8 ratio Group I Group II Group III Group IV
Range 1.87–2.41 0.934–1.415 2.25–4.62 0.537–0.881
Mean ± SD 2.19 ± 0.165 1.10 ± 0.131 3.42 ± 0.575 0.679 ± 0.091
F test 66.171
P value 0.001
I & II I & III I & IV II & III II & IV III & IV
0.001 0.001 0.001 0.001 0.005 0.001
516 B.I. El-Shafey et al.FCS/0.1% NaN3 the cells were permeabilized by using
0.1% saponin/PBS. Thereafter, cells were incubated
with (peridinin–chlorophyll) PerCp-conjugated anti-
IL-4, & (ﬂuorescence isothiocyanate) FITC-conjugatedanti-IFN-c, for 20 min at room temperature in the dark
and then washed twice with 0.1% saponin/PBS. Finally,
the cells were resuspended in PBS and analysed by ﬂow
cytometry. The percentage of positive cells (CD4+/IL-
Table 6 Th1/Th2 ratio in BAL in the 4 groups.
TH1/TH2 ratio Group I Group II Group III Group IV
Range 105.53–254.67 130.95–291.58 144.44–347.62 60.42–261.90
Mean ± SD 153.72 ± 54.84 228.13 ± 48.69 247.26 ± 64.84 165.15 ± 56.05
F test 7.912
P value 0.001
I & II I & III I & IV II & III II & IV III & IV
0.003 0.001 0.638 0.379 0.012 0.001
Table 7 CD4/CD8 ratio in blood in the 4 groups.
CD4/CD8 ratio Group I Group II Group III Group IV
Range 0.926–1.551 0.565–1.069 1.413–2.363 0.430–0.644
Mean ± SD 1.22 ± 0.182 0.826 ± 0.121 1.77 ± 0.230 0.497 ± 0.059
F test 1393.105
P value 0.001
I & II I & III I & IV II & III II & IV III & IV
0.001 0.001 0.001 0.001 0.001 0.001
Table 8 Th1/Th2 ratio in blood in the 4 groups.
TH1/TH2 ratio Group I Group II Group III Group IV
Range 0.051–0.156 0.005–0.009 0.039–0.147 0.002–0.005
Mean ± SD 0.102 ± 0.035 0.006 ± 0.001 0.089 ± 0.021 0.003 ± 0.001
F test 87.242
P value 0.001
I & II I & III I & IV II & III II & IV III & IV
0.001 0.108 0.001 0.001 0.738 0.001
Assessment of treatment response in tuberculous patients 5174+ and CD4+/IFN-c+) was also determined using
isotype-matched IgG antibodies as a control. The rela-
tive ﬂuorescence intensity (RFI) was calculated as inten-
sity of cytokine staining/intensity of isotype matched
control antibody staining according to Nakamura [11].
Results
In BAL, CD4% was signiﬁcantly decreased in group IV as
compared to other groups and there was a signiﬁcant decrease
in group II as compared to groups I and III but group III was
signiﬁcantly increased as compared to group I. CD8% was sig-
niﬁcantly increased in group IV as compared to other groups
and there was a signiﬁcant increase in group II as compared
to groups I and III but group I was signiﬁcantly increased as
compared to group III.Th1% was signiﬁcantly high in group
III as compared to other groups but there was a signiﬁcant
decrease in groups I and IV as compared to groups II but there
was an insigniﬁcant difference between groups I and IV. There
was an insigniﬁcant difference of Th2% was between the 4
studied groups.In blood, CD4% was signiﬁcantly decreased in groups II
and IV as compared to other groups and there was a signiﬁcant
decrease in group IV as compared to group II but group III was
insigniﬁcantly increased as compared to group I. CD8% was
signiﬁcantly increased in groups II and IV as compared to other
groups and there was a signiﬁcant increase in group I as com-
pared to group III but there was an insigniﬁcant difference
between groups II and IV. Th1% was signiﬁcantly decreased
in groups II and IV as compared to other groups but there
was a insigniﬁcant difference between groups I and III and also,
II and IV. Th2% was signiﬁcantly higher in groups II and IV as
compared to other groups and there was a signiﬁcant increase
in group IV as compared to group II but there was a insigniﬁ-
cant difference between groups I and III.
CD4/CD8 ratios in BAL and blood was signiﬁcantly
increased in groups III as compared to other groups and there
was a signiﬁcant increase in group I as compared to groups II
and IV and group IV was signiﬁcantly decreased as compared
to group II. Th1/Th2 ratio in BAL was signiﬁcantly increased
in groups II and III as compared to groups I and IV but there
was a insigniﬁcant difference between groups II, III and I and
IV but in blood was signiﬁcantly increased in groups I and III
518 B.I. El-Shafey et al.as compared to groups II and IV but there was an insigniﬁcant
difference between groups I, III and II and IV.Discussion
This study found that CD4 cells increased in responders but
decreased in active TB and patients with treatment failure in
contrast with, CD8 cells decreased in responders but increased
in active TB and non-responder CD4 cells are most important
in the protective response against M. tuberculosis. In humans,
the pathogenesis of HIV infection has demonstrated that the
loss of CD4 cells greatly increases susceptibility to both acute
and re-activation TB [12]. The primary effect or function of
CD4 cells is the production of IFN-c and possibly other
cytokines, sufﬁcient to activate macrophages. In a murine
model of chronic persistent M. tuberculosis infection [13],
CD4 cell depletion caused rapid re-activation of the infection.
Apoptosis or lysis of infected cells by CD4 cells may also play
a role in controlling infection [14]. CD8 cells are also capable
of secreting cytokines and thus may play a role in regulating
the balance of Th1 and Th2 cells in the lungs of patients with
pulmonary TB. Yu et al., analysed CD4 and CD8 populations
from patients with a rapid, slow, or intermediate regression of
disease while receiving therapy and found that slow regression
was associated with an increase in CD8 cells in the BAL [15].
Taha et al. found increased CD8 T cells in the BAL of patients
with active TB, along with striking increases in the number of
BAL cells expressing IFN c and IL-12 mRNA. These studies
point to a potential role for CD8 cells in the immune response
to TB [16]. M. tuberculosis-infected macrophages appear to be
diminished in their ability to present antigens to CD4 cells,
which leads to persistent infection [17]. In contrast, Nyendak
et al., concluded that mycobacterial tuberculosis speciﬁc
CD8 cell response declines with anti-tuberculosis treatment
but not CD4 and could be a surrogate marker of response to
therapy [18]. An effective T cell response determines whether
the infection resolves or develops into clinically evident dis-
ease. Consequently, there is great interest in determining which
T cells subsets mediate anti-mycobacterial immunity, delineat-
ing their effector functions. On the other hand, many aspects
remain unsolved in understanding why some individuals are
protected from TB infection while others go on to develop dis-
ease. Several studies have demonstrated that CD4 T cells are
involved in protection against TB, as supported by the evi-
dence that CD4 T cell depletion is responsible for TB reactiva-
tion in HIV-infected individuals. There are many subsets of
CD4T cells, such as Th1, Th2, Th17, and regulatory T cells
and all these subsets co-operate or interfere with each other
to control infection; the dominant subset may differ between
active and latent TB infection cases. TB speciﬁc-CD4 Th1 cell
response is considered to have a protective role for the ability
to produce cytokines such as IFN-c or TNF-a that contribute
to the recruitment and activation of innate immune cells, like
monocytes and granulocytes. Thus, while other antigen speciﬁc
T cells such as CD8 T cells, natural killer cells and CD1-re-
stricted T cells can also produce IFN-c during TB infection,
they cannot compensate for the lack of CD4 T cells.
Although the role of CD8 T cells in TB is less clear than
CD4 T cells, they are generally considered to contribute to
optimal immunity and protection. CD8 T cells possess a
number of anti-microbial effector mechanisms that are lessprominent or absent in CD4 Th1 and Th17 T cells and display
a functional proﬁle termed ‘‘multifunctional so it can be a bet-
ter marker of protection in TB than CD4 T cells due to their
release of cytokines or cytotoxic molecules, which cause apop-
tosis of target cells [19]. Tuberculous bacilli resides primarily in
a vacuole within the macrophage, and thus, MHC class II pre-
sentation of mycobacterial antigens to CD4 T cells is an
obvious outcome of infection. These cells are most important
in the protective response against TB. Murine studies with
antibody depletion of CD4 T cells [20] or the use of gene-dis-
rupted mice have shown that the CD4 T cell subset is required
for control of infection. The primary effector function of CD4
T cells is the production of IFN-c and possibly other cytoki-
nes, sufﬁcient to activate macrophages. In CD4 deﬁcient mice,
levels of IFN-c were severely diminished very early in
infection.NOS2 expression by macrophages was also delayed
in the CD4 T cell deﬁcient mice, but returned to wild type
levels in conjunction with IFN c expression. IFN-c levels over-
all were similar in the lungs of CD4 T cell-depleted and control
mice, due to IFN c production by CD8 T cells. Moreover,
there was no apparent change in macrophage NOS2 produc-
tion or activity in the CD4 T cell-depleted mice. This indicated
that there are IFN-c and NOS2-independent, CD4 T cell-de-
pendent mechanisms for control of TB. Therefore, other func-
tions of CD4 T cells are likely to be important in the protective
response and also for the future studies of new vaccine design
against TB [21]. Rozot et al., Concluded that ﬂow cytometry-
based assay and the combination of two immunological mea-
sure; mycobacterial tuberculosis speciﬁc CD4 T-cells and the
detection of mycobacterial tuberculosis speciﬁc CD8 T-cell
responses, represents a powerful diagnostic tool to discrimi-
nate between active TB and latent infection [22]. Afzal con-
cluded that CD4 and CD8 T cells percentages may help to
ﬁnd out the immune status of TB patients before and after
the completion of treatment [23]. BAL Th1% increased in
responder and active TB groups but decreased in non-respon-
ders, Hickman et al. suggested that macrophages and dendritic
cells (DCs), albeit both being APC, respond differently follow-
ing M. tuberculosis infection. DCs only, support Th1 priming
because of their unique ability to make IL-12 in response to
M. tuberculosis infection. Dendritic cells capture antigens of
M. tuberculosis and transport it to the lymph nodes for T cell
priming and Th1 polarization [24]. Zhang et al. studied cyto-
kine production in pleural ﬂuid and found high levels of IL-
12 after stimulation of pleural ﬂuid cells with M. tuberculosis
[25]. Lin et al., observed that TB patients showed evidence of
high IFN c production and no IL-4 secretion by the lympho-
cytes in the lymph nodes [26]. Robinson et al. found increased
levels of IFN-c mRNA in situ in BAL cells from patients with
active pulmonary TB [27]. Condos et al., found that patients
with limited TB have an alveolar lymphocytosis in infected
regions of the lung and these lymphocytes produce high levels
of IFN-c [28]. In the present work, Th1% decreased in blood
of patients with active TB and also, with treatment failure but
increased in responders, reversely, Th2% increased in active
TB and treatment failure but decreased in responders,
Lienhardt found that in Africa, tuberculosis is associated with
low Th1 and high Th2 activity in vivo, whereas close exposure
to tuberculosis is associated with a high Th1/Th2 ratio and
patients with favourable outcome after treatment exhibit a
higher Th1/Th2 ratio compared to patients with poor clinical
outcome [29]. In mice infected with virulent strain of M.
Assessment of treatment response in tuberculous patients 519tuberculosis, initially Th1 like and later Th2 like response has
been demonstrated [30]. Multiple studies concluded that
patients with TB had a Th2-type response in their peripheral
blood, as Huygen et al., reported that PBMC, when stimulated
in vitro with PPD, release lower levels of IFN-c and IL-2, as
compared to tuberculin positive healthy subjects [31], Vilcek
et al., reported reduced IFN-c [32] also, Sanchez et al., found
increased IL-4 secretion [33] and Surcel et al., concluded that
there was increased number of IL-4 secreting cells in pul-
monary TB [34]. Shahemabadi et al., found that IL-12 produc-
tion by monocytes in response toM. tuberculosis total sonicate
antigens was signiﬁcantly decreased in the active TB patients
but IL-10 production showed a signiﬁcant increase in compar-
ison to healthy individuals [35]. The present study found that
Th1% decreased in BAL and blood of patients with treatment
failure, Sodhi et al. [36] have demonstrated that low levels of
circulating IFN-c in peripheral blood were associated with sev-
ere clinical TB and in patients with far advanced or cavitary
disease, no Th1-type lymphocytosis is present. Cozmei et al.,
found that plasma and pleural ﬂuid cytokine analysis at the
outset of tuberculosis disease reﬂect the same Th1 response
dominated by IFN-gamma. In opposition, very low IFN-
gamma levels were recorded in neoplastic pleural ﬂuids [37].
Both types of cytokines (Th1 and Th2) were secreted in
response to in vitro PPD stimulation of PBMCs and had dif-
ferent evolutions in moderate and advanced TB. Thus, IFN-
gamma and IL-4 production after 6 months-treatment
decreased in moderate TB and increased in severe disease.
Experimentally, Th1 polarization is readily transformed to
Th2 dominance through depletion of intracellular glutathione,
and vice versa. Mercury depletes glutathione and polarizes
towards Th2 dominance. Several nutrients and hormones mea-
surably inﬂuence Th1/Th2 balance, including plant sterols/
sterolins, melatonin, probiotics, progesterone, and the miner-
als selenium and zinc. The long-chain omega-3 fatty acids
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic
acid) signiﬁcantly beneﬁt diverse inﬂammatory and autoim-
mune conditions without any speciﬁc Th1/Th2 effect. Th1/
Th2-based immunotherapies, e.g., T-cell receptor (TCR) pep-
tides and interleukin-4 (IL-4) injections, have produced mixed
results to date [8]. It was concluded that CD4 and Th1 cells
increased in responders to anti-tuberculous treatment but
CD8 cells increased in patients with treatment failure locally
and in peripheral blood, also Th2 cells increased in non-re-
sponders only in peripheral blood. So, CD4, CD8, Th1 and
Th2 cells play a major role in immunology against TB infec-
tion and can be used as a marker for response to anti-tubercu-
lous treatment and future studies must be done towards new
treatment used these cells.
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